ReversingLabs classifies $25m series A

The company, which entered into a strategic partnership with In-Q-Tel in 2012, has closed a round co-led by Trident Capital Cybersecurity and JPMorgan Chase.

ReversingLabs, a US-based real-time file analysis and classification technology producer, closed a $25m series A round on Wednesday co-led by financial services firm JPMorgan Chase.

Trident Capital Cybersecurity co-led the funding round.

Founded in 2009, ReversingLabs has developed cybersecurity technology that analyses all files on a company’s network – including email attachments, internet downloads and data from other sources –  to detect threats, similarities to known malware and customised attacks.

The company was previously self-funded, though it inked a strategic partnership with In-Q-Tel, the investment arm of the US intelligence community, in 2012.

The series A funding will allow ReversingLabs to cope with client demand, expand to additional markets and grow its international reach. Sean Cunningham, managing director of Trident Capital Cybersecurity, will join the board of directors.

Mario Vuksan, chief executive at ReversingLabs, said: “We are excited to welcome Trident Capital Cybersecurity and JPMorgan Chase to our team. They are providing capital that allows us to expand our solutions to customers in new markets and industries.

“Their expertise in cybersecurity is very valuable, and we appreciate their recognising ReversingLabs solutions as a critical component in any enterprise looking to enhance their security posture.”

See more from this Government Report: US

Back

Copyright Mawsonia Limited 2010. Please don't cut articles from www.globalgovernmentventuring.com or the PDF and redistribute by email or post to the web without written permission.

Most read

  1. Europe ‘guarantees’ research and innovation budget

    November 28, 2017

  2. Definvest targets startups with $59m

    November 21, 2017

  3. Nautilus sails to $26m series C

    November 22, 2017

  4. Codiak develops $76.5m series C

    November 30, 2017

  5. Step Pharma climbs $17m series A

    November 22, 2017